New drug aims to tame inflammation in kidney patients
NCT ID NCT04626505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug, ziltivekimab, in 36 adults with advanced chronic kidney disease (not on dialysis) to see if it can safely reduce inflammation and related heart risks. Participants received either a low dose, a high dose, or a placebo injection every 4 weeks for 3 doses. The main goal was to measure changes in a blood marker of inflammation (hs-CRP) over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ehime Medical Center
Ehime, 791-0281, Japan